Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10082580 | 1.00 | HPGD (0.50) | HPGDHSD17B10CTSKSMN1; SMN2RECQL | |
| SCHEMBL525478 | 1.00 | HPGD (0.50) | HPGDHSD17B10CTSKSMN1; SMN2RECQL | |
| SCHEMBL889059 | 0.95 | HSD17B10 (0.55) | HPGDHSD17B10CTSKSMN1; SMN2RECQL | |
| SCHEMBL231219 | 0.95 | HSD17B10 (0.55) | HPGDHSD17B10CTSKSMN1; SMN2RECQL | |
| SCHEMBL3188564 | 0.95 | HSD17B10 (0.55) | HPGDHSD17B10CTSKSMN1; SMN2RECQL | |
| SCHEMBL1198458 | 0.92 | PTPN2 (0.47) | HPGDHSD17B10NPC1 | |
| SCHEMBL4919669 | 0.89 | HSD17B10 (0.47) | HPGDHSD17B10CTSKSMN1; SMN2RECQL | |
| SCHEMBL5275535 | 0.89 | HSD17B10 (0.47) | HPGDHSD17B10CTSKSMN1; SMN2RECQL | |
| SCHEMBL7885175 | 0.86 | HPGD (0.48) | HPGDHSD17B10SMN1; SMN2RECQLEPHX1 | |
| SCHEMBL7885177 | 0.86 | HPGD (0.48) | HPGDHSD17B10SMN1; SMN2RECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078121-A1 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | BRIDGE MEDICINES (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4583869-A2 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | Bridge Medicines (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| CN-117858877-A | C-linked inhibitors of ENL/AF9 YEATS | 桥梁药品有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4337662-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | Bridge Medicines (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024054749-A2 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | BRIDGE MEDICINES (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2022240830-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170029427-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9504689-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150238501-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| US-8980878-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | HPGD 2066/4885HSD17B10 1128/4885CTSK 456/4885 |
| US-20150238501-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | HPGD 2066/4885HSD17B10 1128/4885CTSK 456/4885 |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | HPGD 2066/4885HSD17B10 1128/4885CTSK 456/4885 |
| US-20260078121-A1 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | MLLT3, MLLT1, FLT3 | HPGD 4318/4885HSD17B10 2268/4885CTSK 2565/4885 |
| US-20170029427-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | HPGD 2066/4885HSD17B10 1128/4885CTSK 456/4885 |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | HPGD 4028/4885HSD17B10 2328/4885CTSK 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.